Premium
Methoxy polyethylene glycol–cholesterol modified soy lecithin liposomes for poorly water‐soluble anticancer drug delivery
Author(s) -
Le Ngoc Thuy Trang,
Nguyen Dinh Tien Dung,
Nguyen Ngoc Hoi,
Nguyen Cuu Khoa,
Nguyen Dai Hai
Publication year - 2021
Publication title -
journal of applied polymer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.575
H-Index - 166
eISSN - 1097-4628
pISSN - 0021-8995
DOI - 10.1002/app.49858
Subject(s) - polyethylene glycol , liposome , lecithin , cytotoxicity , chemistry , peg ratio , particle size , paclitaxel , conjugate , drug delivery , drug carrier , chromatography , drug , surface charge , in vitro , pharmacology , organic chemistry , biochemistry , chemotherapy , medicine , surgery , mathematical analysis , mathematics , finance , economics
Soy lecithin liposomes (SLP) were prepared and partially surface modified with methoxy polyethylene glycol‐cholesterol conjugate (mPEG‐Chol) to improve its poorly‐soluble‐water‐anticancer‐drugs delivery efficiency. Paclitaxel (PTX) was used as the model drug and the PTX/SLP@mPEG was successfully developed with the optimal mass ratio of mPEG‐Chol determined at 4% in the SLP@mPEG formulation. The optimal SLP@mPEG formulation had a particle size range of 161.80 ± 1.51 nm and a negative surface charge of −54.30 ± 1.40 mV. Besides, a sustained drug release profile of 72 h and an encapsulation efficiency of 87.48 ± 0.70% was recorded. Moreover, in vitro cytotoxicity assays demonstrated that SLP@mPEG is nontoxic and cytocompatible. Overall, these obtained results provide insights into the potential of SLP@mPEG as a platform for the development of more effective therapies against cancers.